Tactile Medical Acquires LymphaTech, Ushering in a New Era of Data-Driven Lymphedema Care

MINNEAPOLIS, MN – February 17, 2026 – In a strategic move poised to reshape the landscape of chronic disease management, Tactile Systems Technology, Inc. (“Tactile Medical”) today announced its acquisition of LymphaTech Inc., a pioneer in digital three-dimensional (3D) body measurement technology. The deal, valued at an upfront cash payment of $6.8 million with potential for future milestone-based considerations, signals a significant shift from product-based treatment to an integrated, data-driven ecosystem for managing lymphedema.

This acquisition brings LymphaTech’s innovative, hand-held scanning platform under the umbrella of Tactile Medical, a longtime leader in at-home therapies for chronic conditions. By merging LymphaTech's advanced diagnostic and monitoring capabilities with its own established therapeutic devices, Tactile Medical aims to create a comprehensive care pathway for the estimated 20 million people in the United States suffering from symptomatic lymphatic dysfunction.

A Digital Leap in Lymphedema Assessment

For decades, the standard for assessing lymphedema—a chronic condition characterized by swelling due to a compromised lymphatic system—has been the simple tape measure. This manual method, while ubiquitous, is notoriously time-consuming, prone to user variability, and often lacks the sensitivity to detect subtle but clinically significant changes in limb volume. This can lead to delays in diagnosis and difficulties in accurately tracking treatment efficacy.

LymphaTech, founded in 2014, was created to solve this very problem. The company developed a clinically validated, portable 3D imaging system that replaces the tape measure with a quick, non-invasive scan. Using a hand-held mobile scanner and proprietary algorithms, the platform captures and generates a precise, clinical-grade 3D model of a patient’s limbs or entire body in moments. It delivers highly accurate fluid volume and circumference measurements, which are critical for both diagnosing lymphedema and tailoring treatment plans.

Clinical research has substantiated the technology's effectiveness. A 2020 study published in the journal Physical Therapy found the LymphaTech system demonstrated excellent reliability and validity for measuring arm volume in women with breast cancer-related lymphedema, with results showing it was 99% as accurate as the gold-standard water displacement method. This level of precision and objectivity represents a paradigm shift, allowing clinicians to make decisions based on robust, repeatable data.

“By introducing greater objectivity and efficiency into assessment, it enhances confidence in clinical decision-making and enables providers to dedicate more time to patient care,” noted Dr. Tony Gasparis, Chief Medical Officer at Tactile Medical, in the company’s official announcement.

From Products to a Comprehensive Care Ecosystem

The acquisition is more than just an addition to Tactile Medical’s product line; it is the cornerstone of a new strategic vision. The company, long known for its at-home pneumatic compression devices, is now positioning itself as an end-to-end solutions provider for lymphatic disease.

“This acquisition is a milestone in Tactile’s evolution from a product-based company to a comprehensive, integrated solutions leader for lymphatic dysfunction,” said Sheri Dodd, Chief Executive Officer of Tactile Medical. “By bringing together Tactile and LymphaTech, we become uniquely positioned to support patients and clinicians from early disease intervention to innovative connected therapies with long-term support and monitoring alongside our Kylee™ patient engagement application.”

This new ecosystem promises a seamless patient journey. A clinician could use the LymphaTech scanner for early and accurate diagnosis, prescribe a Tactile Medical therapy device based on that objective data, and then use the same scanning technology for longitudinal surveillance—tracking swelling changes over time to monitor disease progression and treatment response. This data can be integrated with patient-reported outcomes through the Kylee™ app, creating a holistic view of the patient’s health and empowering more personalized care.

Redefining the Market and Patient Experience

The impact of this integration extends beyond the clinic walls. LymphaTech's platform is already utilized by compression garment manufacturers to digitize the measurement and ordering process. Properly fitted compression garments are a fundamental component of lymphedema management, and inaccuracies in manual measurements often lead to ill-fitting garments, patient discomfort, and costly remakes. By standardizing and digitizing this process, the technology improves fit accuracy, reduces waste, and streamlines a critical workflow for both clinicians and manufacturers.

For patients, this technological advancement offers the promise of a better quality of life. Earlier detection can lead to more timely intervention, potentially slowing the progression of a debilitating chronic disease. More accurate data leads to better-fitting garments and more effective therapy, improving comfort and adherence to treatment regimens. The efficiency of the scanning process—taking seconds instead of many minutes—also reduces the burden of clinical visits.

The strategic value of the acquisition has not gone unnoticed by financial markets. In the wake of positive developments for the company's core business, analysts have shown increased confidence, with firms like Piper Sandler recently raising their price target for Tactile Medical's stock (Nasdaq: TCMD), citing stabilization and growth prospects in its lymphedema business.

Integrating Innovation for Future Growth

To ensure a successful fusion of technologies and cultures, LymphaTech co-founders Mike Weiler, PhD, and Nate Frank, MBA, have joined Tactile Medical. Their new roles will focus on driving commercial adoption of the LymphaTech platform and supporting the ongoing research and development activities that will spring from this new partnership.

This commitment to integrating expertise underscores the forward-looking nature of the acquisition. Tactile Medical isn't just acquiring a product; it's acquiring a wellspring of innovation and deep knowledge in digital health and lymphatic science. As CEO Sheri Dodd noted, the move brings “advanced research competencies and programs that extend LymphaTech’s proprietary capabilities into next-generation approaches for assessment and treatment.”

With this acquisition, Tactile Medical is making a definitive statement about the future of lymphedema management—a future that is digital, connected, and data-driven. By combining best-in-class diagnostics with proven therapies and patient engagement tools, the company is poised to not only solidify its market leadership but also to fundamentally elevate the standard of care for millions of patients worldwide.